In the BioHarmony Drug Report Database

"Preview" Icon

Piperazine

Antepar, Bryrel, Multifuge (piperazine) is a small molecule pharmaceutical. Piperazine was first approved as Antepar on 1982-01-01. It is used to treat ascariasis, enterobiasis, and nematode infections in the USA. It is known to target 5-hydroxytryptamine receptor 2B, muscarinic acetylcholine receptor M4, muscarinic acetylcholine receptor M3, 5-hydroxytryptamine receptor 1D, muscarinic acetylcholine receptor M2, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 1E, muscarinic acetylcholine receptor M5, 5-hydroxytryptamine receptor 7, muscarinic acetylcholine receptor M1, and 5-hydroxytryptamine receptor 6.

 

Trade Name

 

Antepar, Bryrel, Multifuge
 

Common Name

 

piperazine
 

ChEMBL ID

 

CHEMBL1412
 

Indication

 

ascariasis, enterobiasis, nematode infections
 

Drug Class

 

Image (chem structure or protein)

Piperazine structure rendering